https://pharminent.com/uk-partners-with-eli-lilly-on-obesity-plan/ 2026-06-29T15:07:29Z Pharminent en UK partners with Eli Lilly on obesity plan 2026-06-29T13:13:26Z Blog https://pharminent.com/zymeworks-cuts-deal-to-buy-theravance-for-929m-in-cash/ 2026-06-29T15:07:32Z Pharminent en Zymeworks cuts deal to buy Theravance for $929m in cash 2026-06-29T12:09:26Z Blog https://pharminent.com/bridgebios-achondroplasia-pill-shows-compelling-growth-and-body-proportionality-benefit/ 2026-06-29T15:07:33Z Pharminent en BridgeBio's achondroplasia pill shows 'compelling' growth and body proportionality benefit 2026-06-29T11:01:55Z Blog https://pharminent.com/biogen-trims-apellis-pipeline-and-rd-team-after-5-6bn-takeover/ 2026-06-29T15:03:46Z Pharminent en Biogen trims Apellis pipeline and R&D team after $5.6bn takeover 2026-06-29T10:42:49Z Blog https://pharminent.com/lillys-jaypirca-receives-chmp-positive-opinion-for-cll-in-europe-2/ 2026-06-29T15:04:55Z Pharminent en Lilly's Jaypirca receives CHMP positive opinion for CLL in Europe 2026-06-29T07:05:31Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-june-26-2026/ 2026-06-28T19:30:41Z Pharminent en Oncology Intelligence Digest • June 26, 2026 2026-06-28T19:25:59Z Blog https://pharminent.com/week-in-review/week-in-review-intelligence-brief-june-27-2026/ 2026-06-28T19:21:50Z Pharminent en Week in Review • INTELLIGENCE BRIEF • June 27, 2026 2026-06-28T19:21:48Z Blog https://pharminent.com/market-access/market-access-intelligence-weekly-digest-june-26-2026/ 2026-06-27T17:13:15Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • June 26, 2026 2026-06-27T17:13:13Z Blog